A suite of genome-engineered hepatic cells provides novel insights into the spatiotemporal metabolism of apolipoprotein B and apolipoprotein B-containing lipoprotein secretion.

IF 10.2 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Cardiovascular Research Pub Date : 2024-09-21 DOI:10.1093/cvr/cvae121
Amber Meurs, Klevis Ndoj, Marlene van den Berg, Goran Marinković, Matteo Tantucci, Tineke Veenendaal, Jan Albert Kuivenhoven, Judith Klumperman, Noam Zelcer
{"title":"A suite of genome-engineered hepatic cells provides novel insights into the spatiotemporal metabolism of apolipoprotein B and apolipoprotein B-containing lipoprotein secretion.","authors":"Amber Meurs, Klevis Ndoj, Marlene van den Berg, Goran Marinković, Matteo Tantucci, Tineke Veenendaal, Jan Albert Kuivenhoven, Judith Klumperman, Noam Zelcer","doi":"10.1093/cvr/cvae121","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>Apolipoprotein B (APOB)-containing very LDL (VLDL) production, secretion, and clearance by hepatocytes is a central determinant of hepatic and circulating lipid levels. Impairment of any of the aforementioned processes is associated with the development of multiple diseases. Despite the discovery of genes and processes that govern hepatic VLDL metabolism, our understanding of the different mechanistic steps involved is far from complete. An impediment to these studies is the lack of tractable hepatocyte-based systems to interrogate and follow APOB in cells, which the current study addresses.</p><p><strong>Methods and results: </strong>To facilitate the cellular study of VLDL metabolism, we generated human hepatic HepG2 and Huh-7 cell lines in which CRISPR/Cas9-based genome engineering was used to introduce the fluorescent protein mNeonGreen into the APOB gene locus. This results in the production of APOB100-mNeon that localizes predominantly to the endoplasmic reticulum (ER) and Golgi by immunofluorescence and electron microscopy imaging. The production and secretion of APOB100-mNeon can be quantitatively followed in medium over time and results in the production of lipoproteins that are taken up via the LDL receptor pathway. Importantly, the production and secretion of APOB-mNeon is sensitive to established pharmacological and physiological treatments and to genetic modifiers known to influence VLDL production in humans. As a showcase, we used HepG2-APOBmNeon cells to interrogate ER-associated degradation of APOB. The use of a dedicated sgRNA library targeting all established membrane-associated ER-resident E3 ubiquitin ligases led to the identification of SYNV1 as the E3 responsible for the degradation of poorly lipidated APOB in HepG2 cells.</p><p><strong>Conclusions: </strong>In summary, the engineered cells reported here allow the study of hepatic VLDL assembly and secretion and facilitate spatiotemporal interrogation induced by pharmacologic and genetic perturbations.</p>","PeriodicalId":9638,"journal":{"name":"Cardiovascular Research","volume":" ","pages":"1253-1264"},"PeriodicalIF":10.2000,"publicationDate":"2024-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11416059/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/cvr/cvae121","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Aims: Apolipoprotein B (APOB)-containing very LDL (VLDL) production, secretion, and clearance by hepatocytes is a central determinant of hepatic and circulating lipid levels. Impairment of any of the aforementioned processes is associated with the development of multiple diseases. Despite the discovery of genes and processes that govern hepatic VLDL metabolism, our understanding of the different mechanistic steps involved is far from complete. An impediment to these studies is the lack of tractable hepatocyte-based systems to interrogate and follow APOB in cells, which the current study addresses.

Methods and results: To facilitate the cellular study of VLDL metabolism, we generated human hepatic HepG2 and Huh-7 cell lines in which CRISPR/Cas9-based genome engineering was used to introduce the fluorescent protein mNeonGreen into the APOB gene locus. This results in the production of APOB100-mNeon that localizes predominantly to the endoplasmic reticulum (ER) and Golgi by immunofluorescence and electron microscopy imaging. The production and secretion of APOB100-mNeon can be quantitatively followed in medium over time and results in the production of lipoproteins that are taken up via the LDL receptor pathway. Importantly, the production and secretion of APOB-mNeon is sensitive to established pharmacological and physiological treatments and to genetic modifiers known to influence VLDL production in humans. As a showcase, we used HepG2-APOBmNeon cells to interrogate ER-associated degradation of APOB. The use of a dedicated sgRNA library targeting all established membrane-associated ER-resident E3 ubiquitin ligases led to the identification of SYNV1 as the E3 responsible for the degradation of poorly lipidated APOB in HepG2 cells.

Conclusions: In summary, the engineered cells reported here allow the study of hepatic VLDL assembly and secretion and facilitate spatiotemporal interrogation induced by pharmacologic and genetic perturbations.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
一套基因组工程肝细胞为了解 APOB 的时空代谢和含 APOB 脂蛋白的分泌提供了新的视角。
目的:肝细胞产生、分泌和清除含 APOB 的极低密度脂蛋白(VLDL)是决定肝脏和循环血脂水平的核心因素。上述任何一个过程的损伤都与多种疾病的发生有关。尽管发现了支配肝脏 VLDL 代谢的基因和过程,但我们对其中不同机理步骤的了解还远远不够。这些研究的一个障碍是缺乏基于肝细胞的可控系统来询问和跟踪细胞中的 APOB,而目前的研究正好解决了这一问题:为了便于对 VLDL 代谢进行细胞研究,我们生成了人类肝脏 HepG2 和 Huh-7 细胞系,在这些细胞系中,我们使用基于 CRISPR/Cas9 的基因组工程将荧光蛋白 mNeonGreen 导入 APOB 基因位点。这样就产生了 APOB100-mNeon,通过免疫荧光和电子显微镜成像,它主要定位于内质网(ER)和高尔基体。APOB100-mNeon 的产生和分泌可在培养基中随时间定量跟踪,并产生脂蛋白,通过 LDLR 途径被吸收。重要的是,APOB-mNeon 的产生和分泌对已有的药物和生理治疗以及已知会影响人类 VLDL 产生的基因修饰因子很敏感。作为展示,我们使用 HepG2-APOBmNeon 细胞来检测 APOB 的 ER 相关降解(ERAD)。通过使用针对所有已建立的膜相关ER驻留E3泛素连接酶的专用sgRNA文库,我们鉴定出SYNV1是负责降解HepG2细胞中脂质含量低的APOB的E3:总之,本文报道的工程细胞可用于研究肝脏 VLDL 的组装和分泌,并有助于对药物和遗传扰动引起的时空问题进行研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Cardiovascular Research
Cardiovascular Research 医学-心血管系统
CiteScore
21.50
自引率
3.70%
发文量
547
审稿时长
1 months
期刊介绍: Cardiovascular Research Journal Overview: International journal of the European Society of Cardiology Focuses on basic and translational research in cardiology and cardiovascular biology Aims to enhance insight into cardiovascular disease mechanisms and innovation prospects Submission Criteria: Welcomes papers covering molecular, sub-cellular, cellular, organ, and organism levels Accepts clinical proof-of-concept and translational studies Manuscripts expected to provide significant contribution to cardiovascular biology and diseases
期刊最新文献
On the cusps of the second heart field: insights from zebrafish into arterial valve origins and disease. Anaplerotic filling in heart failure: a review of mechanism and potential therapeutics TGF-β signalling: the Dr. Jekyll and Mr. Hyde of the aortic aneurysms. C-C motif chemokine receptor-2 blockade ameliorates pulmonary hypertension in rats and synergizes with a pulmonary vasodilator. Inflammation and heart failure: are we facing a "hedgehog's dilemma"?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1